{"nctId":"NCT02065557","briefTitle":"Efficacy and Safety of Adalimumab in Pediatric Subjects With Moderate to Severe Ulcerative Colitis","startDateStruct":{"date":"2014-10-13","type":"ACTUAL"},"conditions":["Ulcerative Colitis"],"count":101,"armGroups":[{"label":"Adalimumab Induction Standard Dose","type":"EXPERIMENTAL","interventionNames":["Biological: Adalimumab","Biological: Placebo"]},{"label":"Adalimumab Induction High Dose","type":"EXPERIMENTAL","interventionNames":["Biological: Adalimumab"]},{"label":"Adalimumab Induction High Dose - Open Label","type":"EXPERIMENTAL","interventionNames":["Biological: Adalimumab"]},{"label":"Maintenance Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Biological: Adalimumab","Biological: Placebo"]},{"label":"Adalimumab Maintenance Standard Dose","type":"EXPERIMENTAL","interventionNames":["Biological: Adalimumab"]},{"label":"Adalimumab Maintenance High Dose","type":"EXPERIMENTAL","interventionNames":["Biological: Adalimumab"]}],"interventions":[{"name":"Adalimumab","otherNames":["Humira"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Diagnosis of UC for at least 12 weeks prior to screening, confirmed by endoscopy with biopsy.\n* Active ulcerative colitis with a Mayo Score of 6 - 12 points and endoscopy subscore of 2 - 3 despite concurrent treatment with oral corticosteroids or immunosuppressants or both.\n\nExclusion Criteria:\n\n* Subject with Crohn's disease (CD) or indeterminate colitis (IC).\n* Current diagnosis of fulminant colitis and/or toxic megacolon.\n* Subjects with disease limited to the rectum (ulcerative proctitis) during the screening endoscopy.\n* Chronic recurring infections or active tuberculosis (TB).","healthyVolunteers":false,"sex":"ALL","minimumAge":"4 Years","maximumAge":"17 Years","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Co-Primary Endpoint 1: Percentage of Participants Who Achieved Clinical Remission as Measured by Partial Mayo Score (PMS) at Week 8 - Induction Period","description":"The Mayo score is a tool designed to measure disease activity for ulcerative colitis. The PMS (Mayo score without endoscopy) ranges from 0 (normal or inactive disease) to 9 (severe disease) and is calculated as the sum of 3 sub scores (stool frequency, rectal bleeding and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). A negative change in PMS indicates improvement. Clinical remission was defined as a PMS ≤ 2 and no individual subscore \\> 1.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"43.3","spread":null},{"groupId":"OG001","value":"59.6","spread":null},{"groupId":"OG002","value":"53.2","spread":null},{"groupId":"OG003","value":"68.8","spread":null},{"groupId":"OG004","value":"40.6","spread":null},{"groupId":"OG005","value":"58.8","spread":null},{"groupId":"OG006","value":"51.8","spread":null},{"groupId":"OG007","value":"66.7","spread":null}]}]}]},{"type":"PRIMARY","title":"Co-Primary Endpoint 2: Percentage of Participants With Clinical Remission Per Full Mayo Score (FMS) at Week 52 in Week 8 Responders Per PMS - Maintenance Period","description":"The FMS ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy, and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). The PMS (Mayo score without endoscopy) ranges from 0 (normal or inactive disease) to 9 (severe disease) and is calculated as the sum of 3 subscores (stool frequency, rectal bleeding and physician's global assessment). Negative changes indicate improvement. PMS responders are defined as those with a decrease in PMS ≥ 2 points and ≥ 30% from Baseline. Clinical remission per FMS is defined as Mayo Score ≤ 2 and no individual subscore \\> 1.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"33.3","spread":null},{"groupId":"OG001","value":"29.0","spread":null},{"groupId":"OG002","value":"45.2","spread":null},{"groupId":"OG003","value":"37.1","spread":null},{"groupId":"OG004","value":"33.3","spread":null},{"groupId":"OG005","value":"27.3","spread":null},{"groupId":"OG006","value":"42.9","spread":null},{"groupId":"OG007","value":"35.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Ranked Secondary Endpoint 1: Percentage of Participants With Clinical Response Per FMS at Week 52 in Week 8 Responders Per PMS - Maintenance Period","description":"The FMS ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy, and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). The PMS (Mayo score without endoscopy) ranges from 0 (normal or inactive disease) to 9 (severe disease) and is calculated as the sum of 3 subscores (stool frequency, rectal bleeding and physician's global assessment). Negative changes indicate improvement. PMS responders are defined as those with a decrease in PMS ≥ 2 points and ≥ 30% from Baseline. Clinical response per FMS is defined as a decrease in FMS ≥ 3 points and ≥ 30% from Baseline.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"33.3","spread":null},{"groupId":"OG001","value":"61.3","spread":null},{"groupId":"OG002","value":"67.7","spread":null},{"groupId":"OG003","value":"64.5","spread":null},{"groupId":"OG004","value":"33.3","spread":null},{"groupId":"OG005","value":"57.6","spread":null},{"groupId":"OG006","value":"65.7","spread":null},{"groupId":"OG007","value":"61.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Ranked Secondary Endpoint 2: Percentage of Participants With Mucosal Healing at Week 52 in Week 8 Responders Per PMS - Maintenance Period","description":"The FMS ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy, and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). The PMS (Mayo score without endoscopy) ranges from 0 (normal or inactive disease) to 9 (severe disease) and is calculated as the sum of 3 subscores (stool frequency, rectal bleeding and physician's global assessment). Negative changes indicate improvement. PMS responders are defined as those participants with a decrease in PMS ≥ 2 points and ≥ 30% from Baseline. Mucosal healing per Mayo endoscopy subscore is defined as a subscore of ≤ 1.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"33.3","spread":null},{"groupId":"OG001","value":"38.7","spread":null},{"groupId":"OG002","value":"51.6","spread":null},{"groupId":"OG003","value":"45.2","spread":null},{"groupId":"OG004","value":"33.3","spread":null},{"groupId":"OG005","value":"36.4","spread":null},{"groupId":"OG006","value":"48.6","spread":null},{"groupId":"OG007","value":"42.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Ranked Secondary Endpoint 3: Percentage of Participants With Clinical Remission Per FMS at Week 52 in Week 8 Remitters Per PMS - Maintenance Period","description":"The FMS ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy, and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). The PMS (Mayo score without endoscopy) ranges from 0 (normal or inactive disease) to 9 (severe disease) and is calculated as the sum of 3 subscores (stool frequency, rectal bleeding and physician's global assessment). Negative changes indicate improvement. PMS remitters are defined as those participants with a PMS ≤ 2 and no individual subscore \\> 1. Clinical remission per FMS is defined as Mayo Score ≤ 2 and no individual subscore \\> 1.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"37.5","spread":null},{"groupId":"OG001","value":"42.9","spread":null},{"groupId":"OG002","value":"45.5","spread":null},{"groupId":"OG003","value":"44.2","spread":null},{"groupId":"OG004","value":"37.5","spread":null},{"groupId":"OG005","value":"42.9","spread":null},{"groupId":"OG006","value":"44.0","spread":null},{"groupId":"OG007","value":"43.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Ranked Secondary Endpoint 4: Percentage of Participants With Corticosteroid-Free Clinical Remission Per FMS at Week 52 in Week 8 Responders Per PMS - Maintenance Period","description":"The FMS ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy, and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). The PMS (Mayo score without endoscopy) ranges from 0 (normal or inactive disease) to 9 (severe disease) and is calculated as the sum of 3 subscores (stool frequency, rectal bleeding and physician's global assessment). Negative changes indicate improvement. PMS responders are defined as those with a decrease in PMS ≥ 2 points and ≥ 30% from baseline. Among participants receiving systemic corticosteroids at Baseline, corticosteroid-free clinical remission per FMS at Week 52 is defined as having discontinued systemic corticosteroids prior to Week 52 and being in FMS clinical remission at Week 52 (defined as Mayo Score ≤ 2 and no individual subscore \\> 1).","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"40.0","spread":null},{"groupId":"OG001","value":"30.8","spread":null},{"groupId":"OG002","value":"31.3","spread":null},{"groupId":"OG003","value":"31.0","spread":null},{"groupId":"OG004","value":"40.0","spread":null},{"groupId":"OG005","value":"26.7","spread":null},{"groupId":"OG006","value":"35.3","spread":null},{"groupId":"OG007","value":"31.3","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":5,"n":32},"commonTop":["HEADACHE","NASOPHARYNGITIS","COLITIS ULCERATIVE","UPPER RESPIRATORY TRACT INFECTION","ANAEMIA"]}}}